Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Alpha Cognition Inc.

Alpha Cognition Announces Financial Results for the Second Quarter and Six Months Ended June 2024 and Provides Corporate Update
From Alpha Cognition Inc.
Via Business Wire
Tickers ACOG CSE:ACOG
Alpha Cognition Announces Pricing of $50 Million Upsized Public Offering and Nasdaq Listing
From Alpha Cognition Inc.
Via Business Wire
Tickers ACOG CSE:ACOG
Alpha Cognition Announces Proposed Financing and Share Consolidation in connection with Nasdaq Uplisting
From Alpha Cognition Inc.
Via Business Wire
Tickers ACOGF CSE:ACOG
Alpha Cognition Announces Appointment of VP Finance and Accounting
From Alpha Cognition Inc.
Via Business Wire
Tickers ACOGF CSE:ACOG
Alpha Cognition Receives Notice of Allowance for Composition-of-Matter Patent for ZUNVEYLTM for Mild to Moderate Alzheimer’s Disease
From Alpha Cognition Inc.
Via Business Wire
Tickers ACOGF CSE:ACOG
Alpha Cognition Announces Change of Officer
From Alpha Cognition Inc.
Via Business Wire
Tickers ACOGF CSE:ACOG
Alpha Cognition Announces Completion of $4.545 Million (USD) Convertible Note and Warrants Bridge Financing
From Alpha Cognition Inc.
Via Business Wire
Tickers ACOGF CSE:ACOG
Alpha Cognition Receives Notice of Allowance for Composition-of-Matter Patent for ZUNVEYL® for Mild to Moderate Alzheimer’s Disease
From Alpha Cognition Inc.
Via Business Wire
Tickers ACOGF CSE:ACOG
Alpha Cognition, Inc. On Track to Secure Financing for Continued Growth
From Alpha Cognition Inc.
Via Business Wire
Tickers ACOGF CSE:ACOG
Alpha Cognition Announces Financial Results for the Second Quarter and Six Months Ended June 2024 and Provides Corporate Update
From Alpha Cognition Inc.
Via Business Wire
Tickers ACOG CSE:ACOG
Alpha Cognition’s Oral Therapy ZUNVEYL® Receives FDA Approval to Treat Alzheimer's Disease
From Alpha Cognition Inc.
Via Business Wire
Tickers ACOGF CSE:ACOG
Alpha Cognition Files U.S. Patent Application Covering an ALPHA-1062 Oral Formulation to Treat Mild to Moderate Alzheimer’s Disease
From Alpha Cognition Inc.
Via Business Wire
Tickers ACOGF CSE:ACOG
Alpha Cognition Provides Business Update
From Alpha Cognition Inc.
Via Business Wire
Tickers ACOGF CSE:ACOG
Alpha Cognition Announces Final Closing of Private Placement Offering and Completion of the Overallotment
From Alpha Cognition Inc.
Via Business Wire
Tickers ACOGF CSE:ACOG
Alpha Cognition Announces Fourth Closing of Private Placement and Continuation of the Offering
From Alpha Cognition Inc.
Via Business Wire
Tickers ACOGF CSE:ACOG
Alpha Cognition Announces FDA Acceptance of New Drug Application for ALPHA-1062 for Mild-to-Moderate Alzheimer’s Disease
From Alpha Cognition Inc.
Via Business Wire
Tickers ACOGF CSE:ACOG
Alpha Cognition Announces Amended Terms of Private Placement and Continuation of the Offering
From Alpha Cognition Inc.
Via Business Wire
Tickers ACOGF CSE:ACOG
Alpha Cognition Announces Second Closing of Private Placement and Continuation of the Offering
From Alpha Cognition Inc.
Via Business Wire
Tickers ACOGF CSE:ACOG
Alpha Cognition Announces Initial Closing of Private Placement and Pricing for Continuation of the Offering
From Alpha Cognition Inc.
Via Business Wire
Tickers ACOGF CSE:ACOG
Alpha Cognition Launches $6.5 Million Private Placement
From Alpha Cognition Inc.
Via Business Wire
Tickers ACOGF CSE:ACOG
Alpha Cognition Announces Fourth Quarter and Full Year 2022 Results and Provides Corporate Update
From Alpha Cognition Inc.
Via Business Wire
Tickers ACOGF TSX:ACOG
Alpha Cognition Provides Private Placement Update
From Alpha Cognition Inc.
Via Business Wire
Tickers ACOGF TSX-V:ACOG
Alpha Cognition Announces Third Quarter 2022 Results and Provides Corporate Update
From Alpha Cognition Inc.
Via Business Wire
Tickers ACOGF TSX-V:ACOG
Alpha Cognition Announces Second Quarter 2022 Results and Provides Corporate Update
From Alpha Cognition Inc.
Via Business Wire
Tickers ACOGF TSX-V:ACOG
Alpha Cognition Announces Positive Topline Results from Bioequivalence Study with ALPHA-1062 in Development for Alzheimer’s Disease
From Alpha Cognition Inc.
Via Business Wire
Tickers ACOGF TSX-V:ACOG
Alpha Cognition Announces Positive Results from Pivotal Study with ALPHA-1062 in Development for Alzheimer’s Disease
From Alpha Cognition Inc.
Via Business Wire
Tickers ACOGF TSX-V:ACOG
Alpha Cognition Announces Successful Defense of European Patent Covering ALPHA-0602
From Alpha Cognition Inc.
Via Business Wire
Tickers ACOGF TSX-V:ACOG
Alpha Cognition Announces Positive Data from Pre-Clinical Studies and Discovery of GEM Combinations with Potential for Neurodegenerative Disease Treatment
From Alpha Cognition Inc.
Via Business Wire
Tickers ACOGF TSX-V:ACOG
Alpha Cognition Announces Grant of Stock Options
From Alpha Cognition Inc.
Via Business Wire
Tickers ACOGF TSX-V:ACOG
Alpha Cognition Announces First Quarter 2022 Results and Company Update
From Alpha Cognition Inc.
Via Business Wire
Tickers ACOGF TSX-V:ACOG
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.